Biophytis (EPA:ALBPS)

PRESS RELEASE

published on 06/12/2024 at 10:11, 1 year 7 months ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis successfully transfers BIO101 (20-hydroxyecdysone) production to industrial scale with Seqens, enhancing therapeutic solutions for Duchenne Muscular Dystrophy patients

Biophytis Duchenne Muscular Dystrophy BIO101 Seqens 20-hydroxyecdysone
BRIEF

published on 06/12/2024 at 07:05, 1 year 7 months ago

Biophytis Announces Successful Industrial Transfer of BIO101 Production by Seqens

Biophytis Clinical Trial Duchenne Muscular Dystrophy BIO101 Seqens
REGULATED PRESS RELEASE

published on 06/12/2024 at 07:00, 1 year 7 months ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis announces successful industrial transfer of BIO101 (20-hydroxyecdysone) production by Seqens for DMD treatment. Collaboration strengthens therapeutic solutions and accelerates clinical programs

Biophytis Clinical Development Duchenne Muscular Dystrophy BIO101 Seqens
BRIEF

published on 06/10/2024 at 08:23, 1 year 7 months ago

Biophytis Files IND Application for Phase 2 Obesity Study with US FDA

FDA Biophytis Clinical Study Obesity IND Application
BRIEF

published on 06/10/2024 at 08:21, 1 year 7 months ago

Biophytis files IND application for phase 2 study in obesity

FDA Biophytis Phase 2 BIO101 Obesity
REGULATED PRESS RELEASE

published on 06/10/2024 at 08:18, 1 year 7 months ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis files IND application with US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone) to assess muscle strength improvement in lower limbs and secondary endpoints like mobility and body composition

FDA Biophytis BIO101 IND Application Obesity Study
PRESS RELEASE

published on 06/10/2024 at 08:16, 1 year 7 months ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis submits IND application to US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone). Study to assess muscle strength & body composition. Research led by Professor Marc-André Cornier

Biophytis BIO101 IND Application Obesity Study Professor Marc-André Cornier
BRIEF

published on 06/07/2024 at 08:28, 1 year 7 months ago

Biophytis Announces Combined General Meeting on June 24, 2024

Shareholders Biophytis General Meeting Voting Agenda
REGULATED PRESS RELEASE

published on 06/07/2024 at 08:23, 1 year 7 months ago

Combined General Meeting of June 24, 2024
Biophytis SA to hold Combined General Meeting (CGM) on June 24, 2024 in Paris. Shareholders encouraged to vote in advance via multiple methods. Details available on the company's website

Shareholders Voting Combined General Meeting Biophytis SA CGM
BRIEF

published on 06/07/2024 at 07:44, 1 year 7 months ago

Biophytis Combined General Meeting scheduled for June 24, 2024

Shareholders Biophytis Paris General Assembly Vote

Published on 01/31/2026 at 03:15, 7 hours 6 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 8 hours 1 minute ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 8 hours 41 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 10 hours 21 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 11 hours 21 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 02:45, 7 hours 35 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 12 hours 21 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 14 hours 10 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 14 hours 11 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 14 hours 13 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches

View all EQS

Published on 01/30/2026 at 17:45, 16 hours 36 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 1 day 2 hours ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 16 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 16 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 16 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News